Advertisement

Pituitary Adenoma

  • Katelyn M. Atkins
  • Marc Bussière
  • Helen A. Shih
Chapter

Abstract

Pituitary adenomas represent a heterogeneous group of benign tumors that can present as an incidental radiographic finding or with a variety of neurologic and/or endocrine symptoms. Stereotactic radiosurgery and conventionally fractionated radiotherapy are well-established treatments for pituitary adenoma with high local tumor control rates and extensive long-term follow-up data. There has also been recent clinical interest in the application of FSRT in patients with large tumors or those abutting or involving the optic apparatus. This chapter summarizes hypofractionated radiotherapy techniques, including SRS and FSRT, for pituitary adenomas.

Keywords

Pituitary adenomas Stereotactic radiosurgery SRS FSRT Hypofractionation 

References

  1. 1.
    Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 1969;16:185–217.CrossRefPubMedGoogle Scholar
  2. 2.
    Stoller JKM, Franklin A, Mandell BF. Pituitary disorders and multiple endocrine neoplasia syndromes. In: The cleveland clinic foundation intensive review of internal medicine. Hagerstwon, MD: Lippincott Williams & Wilkins; 2009. p. 525–35.Google Scholar
  3. 3.
    Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg. 1998;88(6):1002–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Sheehan JP, Niranjan A, Sheehan JM, Jane JA Jr, Laws ER, Kondziolka D, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg. 2005;102(4):678–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Mitsumori M, Shrieve DC, Alexander E 3rd, Kaiser UB, Richardson GE, Black PM, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys. 1998;42(3):573–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485–534.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee NY, Riaz N, Lu JJ. Target volume delineation and field setup: a practical guide for conformal and intensity-modulated radiation therapy. Heidelberg: Springer; 2015.CrossRefGoogle Scholar
  8. 8.
    Balagamwala EH, Suh JH, Barnett GH, Khan MK, Neyman G, Cai RS, et al. The importance of the conformality, heterogeneity, and gradient indices in evaluating gamma knife radiosurgery treatment plans for intracranial meningiomas. Int J Radiat Oncol Biol Phys. 2012;83(5):1406–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96(7):1992–2003.CrossRefPubMedGoogle Scholar
  10. 10.
    Iwata H, Sato K, Tatewaki K, Yokota N, Inoue M, Baba Y, et al. Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-Oncology. 2011;13(8):916–22.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S28–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Tishler RB, Loeffler JS, Lunsford LD, Duma C, Alexander E 3rd, Kooy HM, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys. 1993;27(2):215–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37(8):4078–101.CrossRefPubMedGoogle Scholar
  14. 14.
    Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg. 2007;106(5):833–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Iwai Y, Yamanaka K, Yoshioka K. Radiosurgery for nonfunctioning pituitary adenomas. Neurosurgery. 2005;56(4):699–705; discussion 699-705CrossRefPubMedGoogle Scholar
  17. 17.
    Mingione V, Yen CP, Vance ML, Steiner M, Sheehan J, Laws ER, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg. 2006;104(6):876–83.CrossRefPubMedGoogle Scholar
  18. 18.
    Voges J, Kocher M, Runge M, Poggenborg J, Lehrke R, Lenartz D, et al. Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer. 2006;107(6):1355–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Liscak R, Vladyka V, Marek J, Simonova G, Vymazal J. Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir. 2007;149(10):999–1006; discussionCrossRefPubMedGoogle Scholar
  20. 20.
    Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys. 2008;70(5):1325–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML. Gamma knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg. 2011;114(2):303–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Puataweepong P, Dhanachai M, Hansasuta A, Dangprasert S, Swangsilpa T, Sitathanee C, et al. The clinical outcome of hypofractionated stereotactic radiotherapy with cyberknife robotic radiosurgery for perioptic pituitary adenoma. Technology in cancer research & treatment; 2015.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Katelyn M. Atkins
    • 1
  • Marc Bussière
    • 2
  • Helen A. Shih
    • 2
  1. 1.Department of Radiation OncologyMassachusetts General HospitalBostonUSA
  2. 2.Department of Radiation OncologyMassachusetts General Hospital, Francis H. Burr Proton Therapy CenterBostonUSA

Personalised recommendations